Compare Msci Inc (MSCI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs TransMedics Group Inc — how do they compare? Msci Inc trades at $565.48 (market cap $40.38B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Msci Inc is far larger — about 14.7× TransMedics Group Inc's market cap, and Msci Inc pays a 1.48% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and TransMedics Group Inc for 24 Days on average.
| MSCI | TMDX | |
|---|---|---|
Market Cap | $40.38B | $2.74B |
Volume | 414,140 | 949,331 |
Sector | Financials | Health |
52-Week High | $643.83 | $150.42 |
52-Week Low | $511.84 | $61.99 |
Typical Hold Time | 82 Days | 24 Days |
Enterprise Value | $46.54B | $3.13B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $563.55, up 1.47% today, with a bullish technical signal and strong fundamentals including 40.73% net income margin and consistent revenue growth. Recent news highlights the completion of the First Street acquisition and upcoming Q3 2026 earnings call, reinforcing its strategic expansion in climate risk analytics.
The outlook is positive with a consensus price target of $701.71, though high valuation ratios and a recent earnings miss pose risks. Long-term growth is supported by recurring revenue streams and market leadership in index and analytics services.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
